Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise that its wholly owned Canadian subsidiary, Mernova, continues to make strong operational progress. Highlights: Additional product launches across various provinces in addition to those previously announced Agreement with Best Kind Edibles signed for manufacturing of cannabis edibles as an extension to existing product suite Q2 confirmed purchase orders of $1.3m to date, highlighting ongoing strength of Ritual brand at the midpoint of the quarter Purchase orders follow unaudited Q1 revenues of $1.75m ..read more

Since the legalisation of medical cannabis in 2016, Australia has been steadily developing its marijuana industry — and it’s been attracting attention from international players and investors. With a quickly growing population of over 27 million people and a robust agricultural industry, the country could be positioned to mould itself into a major force in the international cannabis space. Here the Investing News Network takes a look at how the cannabis industry in Australia has been shaping up since legalisation. Read on to see what you need to know about investing in cannabis down under. A ..read more

Major cannabis industry player Tilray Brands (TSX:TLRY,NASDAQ:TLRY) disappointed investors with its latest quarterly results this week, falling short of analysts' expectations in the wake of a number of acquisitions. Meanwhile, Nebraska lawmakers have proposed a lower tax rate for CBD after their initial offer was criticized, and unionized cannabis workers are preparing to strike on 4/20 as they seek improved benefits. Stay up to date on the latest news, trends and policy developments in the cannabis industry with our round-up below. Tilray's latest quarterly results disappoint Tilray releas ..read more

Notice is hereby given that the Annual General Meeting (‘Meeting’) of Shareholders of Melodiol Global Health Limited (‘Company’) will be held by virtual meeting facility at 9.30am (WST) on Friday, 31 May 2024. In accordance with section 110D of the Corporations Act 2001 (Cth) (as inserted by the Corporations Amendment (Meeting and documents) Act 2022 (Cth)), the Company will not be dispatching physical copies of the Notice of Meeting (‘Notice’) unless specifically requested to do so. Instead, a copy of the Notice is available on the Company’s ASX Announcement Platform at www2.asx.com.au (ASX ..read more

The Associated Press reported Tuesday (April 30) that the US Drug Enforcement Administration (DEA) was on the cusp of rescheduling cannabis from a Schedule I substance, the same category as heroin and methamphetamines, to Schedule III. The Department of Health and Human Services suggested cannabis be reclassified on August 29, 2023, and the DEA has been deliberating on the decision for months, urged by lawmakers to heed the recommendation. According to the report, Attorney General Merrick Garland was scheduled to submit the proposal to the White House Office of Management and Budget on Tuesd ..read more

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to provide the following update on progress for the three month period ended 31 March 2024 (the ‘quarter’), as well as its Appendix 4C. All financial results are in Australian dollars and unaudited (unless otherwise stated). Highlights: Q1 FY24 unaudited revenue of $4.4m – marks a 91% increase on the prior corresponding period (‘PCP’) Results underpinned by Mernova Medicinal Inc., which delivered $1.6m in revenue during Q1 FY24 Wholly-owned operating division Health House International generated $2.4m in reven ..read more

Notice is hereby given that an Extraordinary General Meeting of Shareholders of BPH Global Limited ACN 009 104 330 will be held at 3:00pm AEST on 24 May 2024 at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 (Meeting). The Explanatory Statement to this Notice of Meeting provides additional information on matters to be considered at the Extraordinary General Meeting. The Explanatory Statement and the Proxy Form forms part of this Notice of Meeting. The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vo ..read more

Several Republican Party members have sent a letter to the US Drug Enforcement Administration (DEA) urging it to reject the US Department of Health and Human Services' recommendation to reschedule cannabis. Meanwhile, the DEA spoke publicly about the rescheduling process for the first time, and lawmakers in New Hampshire voted to reject a proposed amendment to a cannabis legalization bill, putting its future in the Senate in doubt. Stay up to date on the latest news, trends and policy developments in the cannabis industry with our round-up below. DEA addresses cannabis rescheduling timeline ..read more

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise that its wholly owned Australian subsidiary, Health House Australia, continues to make strong operational progress. Highlights: Health House Australia announces the planned launch of its medicinal cannabis clinic in Q2 of 2024 The group is also pleased to announce that it has added several new suppliers during Q1 of 2024 Health House Australia was a key contributor to Melodiol group FY 2023 revenues of $21.6m (an increase of 148% on FY 2022) Health House Australia and Health House UK contributed $11 ..read more

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) investigating new treatments for mental health and select neurological conditions, is pleased to announce it has entered into a binding research study agreement with charity Reach Wellness to manage a pivotal observational study designed to evaluate the effectiveness of Emyria’s MDMA-assisted therapy (MDMA-AT) program, together with a support program managed by Reach Wellness, for first responders with PTSD. The agreement underscores Emyria's leadership in the evolving field of MDMA-AT research and marks a significant step forward in add ..read more